Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ)

CNY 25.59

(0.35%)

Market Cap (In CNY)

3.34 Billion

Revenue (In CNY)

602.28 Million

Net Income (In CNY)

-120.82 Million

Avg. Volume

952 Thousand

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
18.8-36.19
PE
-
EPS
-
Beta Value
-0.332
ISIN
CNE1000034C5
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ya Chen
Employee Count
-
Website
https://www.hiteck.com.cn
Ipo Date
2017-08-08
Details
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye, an acyclovir dispensable tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository drug; Xunkeyuan, a tinidazole suppository drug; and Shufu, a nimodipine sustained release tablets. The company also provides measles virus and rubella virus nucleic acid detection kit; mycoplasma isolation and identification kit and culture tube; bacterial vaginosis rapid detection kit; measles virus IgG antibody detection kit; and coronavirus N-protein detection kit. In addition, it offers Lopinavir and Ritonavir APIs; and intermediates. The company offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.